Shanghai Sonyt Biotechnology Co., Ltd. is one of the leading manufacturers and suppliers of cas:139570-93-7:zoptarelin doxorubicin in China, also supports custom service. Welcome to wholesale bulk high quality cas:139570-93-7:zoptarelin doxorubicin from our factory. Contact us for more details.
| Product Name | CAS:139570-93-7:Zoptarelin doxorubicin |
| Description | Zoptarelin doxorubicin is a peptide-drug conjugate (PDC). It uses a high-affinity LHRH agonist peptide as the targeting carrier to directionally deliver the cytotoxic drug doxorubicin to tumor cells with high LHRH receptor expression (prostate cancer, breast cancer, endometrial cancer), and releases the drug inside the tumor to exert killing effect, significantly reducing the systemic toxic side effects of chemotherapeutic drugs. Applied in targeted antitumor research, peptide drug conjugation technology, and reproductive system tumor targeted therapy research. |
| Peptide Purity (HPLC, %) | 90%/95%/98% |
| Theoretical molecular weight (Da) | ~1700 (subject to actual batch) |
| Structure type | Peptide-small molecule conjugate, cleavable linker |
Product Basic Information Table
| Product Standard English Name | Product Abbreviation / Alias | Function Tags (comma-separated) | Core Structure | Molecular Formula | Exact Mass (Da) | Average MW (Da) | Structure Type | Target Receptor |
| Zoptarelin doxorubicin | Zoptarelin doxorubicin; LHRH-targeted doxorubicin conjugate; AN-152 | Targeted antitumor,Peptide-drug conjugate,LHRH receptor targeting,Prostate cancer research,Reduced chemotherapy toxicity,Reproductive system tumors | LHRH agonist decapeptide + cleavable linker + doxorubicin anthracycline pharmacophore | Large conjugate, no precise small-molecule formula; subject to actual batch MS | - | ~1700 (theoretical) | Peptide-small molecule conjugate | LHRH receptor (GnRHR) |
Physicochemical Solubility & Storage Parameters
| Product Code | Appearance | Long-term Storage Conditions | Short-term Storage Conditions | Liquid Stability | Solid Powder Stability |
| PEP-ZOP001 | Orange-red powder | Store at -20℃, strictly protected from light, sealed and dry, aliquoted. **Cytotoxic, handle with protection** | Solid powder stable for 1 year at 2-8℃ sealed in dark; prepare aqueous solutions freshly before use | Stable for 48 h at 4℃ in dark; stable for 2 weeks at -20℃ in aliquots. **Moderate water solubility, freely soluble in aqueous organic solvents and acidic buffers**. Anthracycline structure highly sensitive to light and prone to oxidative degradation. Linker easily cleaved under acid/base and enzymatic conditions to release drug | Stable for 2 years at -20℃ under dry & dark conditions |
Functional Description
| Product Code | Frontend Short Summary (for search list display) | Detailed Biological Function Description | Applicable Research Areas (comma-separated) | Targets / Pathways |
| PEP-ZOP001 | LHRH-targeted peptide-drug conjugate that directionally delivers doxorubicin to kill tumors and reduces systemic chemotherapy toxicity | Zoptarelin doxorubicin is a classic targeted peptide-drug conjugate, formed by conjugating LHRH agonist peptide with doxorubicin via a cleavable linker. Its targeting carrier peptide binds with high specificity to LHRH receptors highly expressed on the surface of tumor cells, mediates endocytosis of the conjugate into cells, and the linker is cleaved under the action of intracellular acidic environment and enzymes, releasing active doxorubicin, which intercalates into DNA and inhibits topoisomerase II, blocking nucleic acid synthesis and inducing tumor cell apoptosis. Compared with free doxorubicin, it significantly increases the drug concentration at the tumor site, reduces drug exposure to normal tissues such as heart and bone marrow, and significantly reduces toxic side effects. This molecule serves as a core tool for peptide drug conjugation technology research, reproductive system tumor targeted therapy, and chemotherapy toxicity reduction protocol optimization. | Prostate cancer research,Breast cancer research,Peptide drug conjugation technology,Targeted antitumor research,Chemotherapy toxicity reduction,Reproductive endocrine tumors | Gonadotropin-Releasing Hormone Receptor (GnRHR/LHRHR); Topoisomerase II inhibition; DNA damage and tumor cell apoptosis pathway |
Hot Tags: cas:139570-93-7:zoptarelin doxorubicin, China cas:139570-93-7:zoptarelin doxorubicin manufacturers, suppliers, factory, 1415456-99-3, 2381089-83-2, BPC 157, Cagrilintide, CAS 2381089 83 2, Melanotan II
